key: cord-0888579-9fmxz5as
authors: Annane, Djillali
title: Corticosteroids for COVID-19
date: 2021-03-01
journal: nan
DOI: 10.1016/j.jointm.2021.01.002
sha: 7d2bd198af4c0aa784f6523d664b236f9cafc906
doc_id: 888579
cord_uid: 9fmxz5as

COVID-19 is placing a major burden on healthcare, economy and social systems worldwide owing to its fast spread and unacceptably high death toll. The unprecedented research effort has established the role of a deregulated immune response to the severe acute respiratory syndrome coronavirus 2 resulting in systemic inflammation. Thereafter, the immunomodulatory approach has been place in the top list of the research agenda for COVID-19. Corticosteroids have been used for more than 70 years for modulating immune response in a broad variety of disease. These drugs have been shown to prevent and attenuate the inflammation both in tissues and in the circulation via non-genomic and genomic effects. At the bedside, numerous observational cohorts have been published the past months and have been inconclusive. Randomized controlled trials with subsequent high quality meta-analyses have provided moderate to strong certainty for increased chance of survival and relief from life supportive therapy with corticosteroids given at a dose of 6mg per day of dexamethasone or equivalent doses of hydrocortisone or methylprednisolone. The corticotherapy was not associated with increased risk of bacterial infection or of delayed viral clearance. In daily practice, physicians may be encouraged to use to corticosteroids when managing patients with COVID-19 requiring oxygen supplementation.

Coronavirus disease 19 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in Wuhan China in December 2019 [1] . Then, the virus spread in a pandemic manner and, as of November 9 th 2020, affects 50, 446, 517 people worldwide and has killed 1,256,869 people [2] . SARS-CoV-2 is a single stranded RNA virus, and classified as a beta coronavirus. Its subunit S1 of the spike, a structural protein of the virus, is responsible for virus binding to host cell receptors such as angiotensin-converting enzyme 2 receptor, and the subunit S2 contributes to the fusion of the virus membrane with cell's membrane [3] . After the binding process, the spike proteins are activated by proteases, particularly at furin cleavage site, ubiquitously expressed, making SARS-CoV-2 very pathogenic. The penetration of the virus into lung epithelial cells will release danger associated molecular patterns that will activate resident macrophages and dendritic cells with subsequent release of the inflammasome [4] . As long as the virus direct and indirect cytoxicity remains located to the epithelium, the disease remains characterized by mild to moderate lung inflammation. When the endothelium is damaged by direct viral invasion of endothelial cells or by the inflammasome [5] , then systemic hyper-inflammation and multi-organs dysfunction become the hallmark of COVID-19 [6] . Therefore, modulating the immune host response to SARS-CoV-2 have been rapidly considered as a top priority for the international research agenda in the fight against the COVID-19 [7] . Among the drugs that target the immune system, corticosteroids are the most commonly used in the routine management of a broad variety of acute and chronic inflammatory disorders and autoimmune diseases. This article summarizes the current knowledge about the rationale and practical modalities for the use of corticosteroids in patients with COVID-19.

Physicians rapidly recognized that in oxygen-dependent COVID-19 patients, circulating levels of the acute phase reaction proteins, C-reactive protein and serum amyloid A, were increased and prealbumin levels were decreased [8] . Likewise, these patients have increased circulating levels of proinflammatory cytokines such as interleukin (IL)-6, tumor necrosis (TNF)-, IL-1, IL-2, IL-7, and IL-17 [9, 10] . Deregulated interferon-I response also likely contributes to pathological damages to the lungs and other organs in severe COVID-19 [11] . More specifically, abnormal up-regulation of neutralizing auto-antibodies against type I IFNs may contribute to critical illness in COVID-19 patients by impairing the binding of type I IFNs to their receptor downstream signaling [12] . The increase in the proinflammatory cytokines parallels clinical severity and the higher IL-6 and TNF- the higher the risk of death from COVID- 19 [13] . While plasma levels of proinflammatory cytokines have been 4 described as being higher than in other community acquired pneumonia [14] , they may mimic those reported in sepsis or ARDS [15] . In practice, the degree of circulating pro-inflammatory mediators varied fairly between studies [16] . On the one hand, comprehensive immune analysis of peripheral blood cells in severe COVID-19 found alterations similar to those observed during sepsis, e.g. decreased expression of CD16 by neutrophils, monocytes, granulocytes and decreased expression of HLA-DR on monocyte surface [17] . On the other hand, the same analyses found alterations specific to SARS-CoV 2 such as expansion of plasmablasts and activated T cells [18] . The immune response to SARS-CoV-2 appears complex and heterogeneous. Some patients showed robust T and B cells activation and proliferation while in about one out of five patients there was minimal immune response compared to controls [18] . Moreover, among patients who mounted a lymphocytes response there was substantial heterogeneity in the immune profiles with potentially three distinct immune responses, with robust activation of CD4 T cells (immunotype 1), mild activation of CD4 T cells (immunotype 2) or lack of detectable lymphocytes response (immunotype 3) [18]. Immunotype 1 was associated with more severe COVID-19.

Corticosteroids have pleiotropic effects resulting from complex molecular mechanisms including non-genomic and genomic effects [19] . We have recently summarized the molecular basis underlying the benefits of corticosteroids in severe infections [20] . Briefly, glucocorticoids exerts anti-inflammatory by stimulating the synthesis and release of anti-inflammatory proteins and by inhibiting that of pro-inflammatory proteins.

Glucocorticoids bind to the glucocorticoid receptor (GR) located in the cytoplasm of almost all cells. Upon binding with glucocorticoids, the GR dissociates from chaperone proteins heat-shock proteins 70 (Hsp70), Hsp90, and immunophilin [21] . Then, it enters into the nucleus to interact with specific DNA sequences (glucocorticoid responsive elements) of the regulatory region of target genes with subsequent chromatin remodeling [22, 23] . Activated GR represses the expression of pro-inflammatory genes by inhibiting histone acetyltransferases and activating histone deacetylases. For instance, the expression of the IRF3 transcription factor, implicated in interferon production and viral protection, is down-regulated by glucocorticoids [24, 25] . The GR-glucocorticoid complex also inhibits the production of pro-inflammatory proteins by sequestration of NF-κB within the cytosol through increased expression of the inhibitory protein IκBα [26] . Glucocorticoids induce the expression of glucocorticoid-induced leucine zipper (GILZ), an inhibitor of NF-κB [27] , and of the anti-inflammatory protein MAP kinase phosphatase 1, which inhibits nuclear translocation of transcription factor GATA-3 implicated in Th2 type cytokine expression [28] . They promote the production of annexin 1, thereby inhibiting the expression of phospholipase A2, and enhancing the resolution of inflammation and the phagocytosis by macrophages of apoptotic neutrophils [29] .

Glucocorticoids suppress the production of acute phase reactants and of chemokines [30, 31] , thereby preventing leucocytes recruitment. They suppress the expression of endothelial-leukocyte adhesion molecule 1 (ELAM-1), intracellular adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1) opposing to leucocytes diapedesis [32, 33] . Target cells for glucocorticoids include 1) myeloid cells: macrophages, monocytes, tissue resident, migratory and plasmacytoid dendritic cells (DC), and granulocytes 2) lymphocytes: CD8, Th1, Th2 and Th17 as well as Treg and B cells [19, 20] . Glucocorticoids repress the maturation, differentiation and proliferation of all subtypes of leucocytes. [19, 20, 45] .

Although this was a narrative review, the author searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2020 Issue 12) using the search terms 'COVID', 'COVID-19, 'coronavirus', 'SARS', 'SARS-CoV', 'steroids' and 'corticosteroids'. We will also search (up to December 2020) MEDLINE, EMBASE and Latin American Caribbean Health Sciences Literature (LILACS). The author included observational cohort and randomized trials where the participants were patients with suspected or proven COVId-19, and the interventions were oral or intravenous corticosteroids. The author focused on all-cause mortality in the short-term as the primary outcome. The risk for secondary infections, more specifically ventilator associated pneumonia and bacteremia, and the risk for delayed viral clearance were also analyzed. We calculated a weighted treatment effect across trials. We expressed results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes. We considered methods based on the random-effects model for all analyses, as serious heterogeneity across studies was expected. We analyzed separately observational cohorts and randomized trials. In the analysis of randomized trials, sensitivity analysis was performed according to the use of placebo or usual care as the comparator. All analyses were done using Review Manager 5.3 software.

There were several reports about observational cohorts on the use of corticosteroids in patients with COVID-19 [1, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . Table 1 summarizes the main characteristics of these observational studies. Most studies were performed in China. Most studies were single center, and the sample size varied from 31 to 2135 patients. These cohort studies provided data on mortality in the short term, i.e. in-hospital mortality, or mortality at two weeks or one month. When authors provided details about the interventions, methylprednisolone was the most commonly used, at an average dose of 0.5 to 2 mg/kg/day for an average duration of 5 to 10 days. Studies have enrolled adults with a median age from 39 to 68 years, and a majority of males. Studies have occasionally enrolled severe COVID-19 requiring invasive mechanical ventilation. Data from 14 observational studies accounting for 4847 patients with COVID-19 found a risk ratio for short term mortality of 0.86 (95% confidence interval, 0.58 to 1.27; random effect models) (figure 1). There were 436/1893 versus 536/2954 deaths in the corticosteroid-treated patients compared to corticosteroidfree patients. There was strong heterogeneity across the studies (squared I statistic 87%) mainly related to the heterogeneit y of disease severity, of treatment modalities.

Eight randomized controlled trials have investigated the benefit and risk of corticotherapy in patients with . The main characteristics of these trials are summarized in Table 2 . There were three placebo-controlled, double blind trials [63, 64, 65] [66] . These trials accounted for 7737 patients with COVID-19. There were 749/2848 (26.3%) and 1347/4889 (27.6%) deaths in the short-term in the corticosteroids-treated and corticosteroids-free patients, respectively. The corresponding pooled relative risk for short term mortality was 0.90 (95% confidence interval: 0.83 to 0.97, P=0.006, I 2 = 0%, random effect models) in favor or corticosteroids (figure 2). Corticosteroids were generally associated with improved respiratory support free days [60] [61] [62] and improved cardiovascular support free days [60] . There was no evidence from data available in randomized controlled trials for any increase in the risk of superinfection with corticotherapy ( Figure 3 ). The pooled relative risk for any secondary bacterial infection or sepsis was 0.91 (three trials; 95% confidence interval: 0.76 to 1.10, P=0.33, I 2 = 0%, random effect models). The RR for ventilator associated pneumonia and for bacteremia were 0.83 (95% confidence interval: 0.50 to 1.38) and 0.96 (95% confidence interval: 0.55 to 1.68), respectively. Likewise, data from one study did not suggest any delay in viral clearance from the airway by corticotherapy [63] . One trial suggested that patients who do not require oxygen supplementation draw no benefit from or might be harmed by dexamethasone as well as those whom duration of disease was lower than 7 days at time of randomization [59]. Another trial found that patients older than 60 years are more likely to draw survival benefit than younger patients [63] . Table 3 summarizes the characteristics and main finding from 13 systematic reviews and meta-analyses published since March 2020 [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] .

Two of these systematic reviews included only randomized controlled trials [76-77]. The number of accumulated patients ranged from 542 to results of the systematic reviews was related to the date of publication, target population and type of studies. The two systematic reviews that included only randomized controlled trials found an odds ratio for short term deaths of 0.66 (95% confidence interval, 0.53 to 0.82) [76] and of 0.87 (95% credible interval 0.77 to 0.98) [77] in favor of corticosteroids. These meta-analyses suggested that corticosteroids were not associated with increased rate of serious adverse events. The WHO prospective meta-analysis found no evidence that response to corticosteroids may vary with age, gender, duration of the disease before initiating treatment, the dose and type of corticosteroids [76] .

In COVID-19, like in bacterial sepsis, the deregulation of the immune host response results in the most severe cases in overwhelming systemic inflammation. Corticosteroids are potent immunomodulatory drugs that may via genomic and non-genomic effects help preventing or attenuating the hyper-inflammation state that characterized severe SARS-CoV-2 infections. While data from observational cohorts were inconclusive, data from randomized controlled trials and high quality systematic reviews and meta-analyses strongly support the use of corticosteroids in patients with COVID-19 that require oxygen support. Corticosteroids should not be given in patients who do not require oxygen supplementation.

Corticosteroids should be given intravenously or orally, pending of clinical severity of illness, as dexamethasone, hydrocortisone, or methylprednisolone, at dose equivalent to 6 mg of dexamethasone and for 5 to 10 days. 

Clinical characteristics of coronavirus disease 2019 in China

COVID-19 pathophysiology: A review

Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression

COVID-19: the vasculature unleashed

Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19

Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine, 100590. Advance online publication

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Immune regulation by glucocorticoids

Reduced levels of hsp90 compromise steroid receptor action in vivo

The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain

The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression

The GRIP1:IRF3 interaction as a target for glucocorticoid receptormediated immunosuppression

Molecular determinants of crosstalk between nuclear receptors and toll-like receptors

Molecular Control of Immune/Inflammatory Responses: Interactions Between Nuclear Factor-κB and Steroid Receptor-Signaling Pathways

Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an antiinflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10

Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38

Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis

Glucocorticoids inhibit chemokine generation by human eosinophils

Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines

A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data

Prolonged Low-Dose Methylprednisolone in Patients With Severe

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report. The New England journal of medicine

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid)

ISARIC_ Data_Platform_COVID-19_Report_13JUL20.pdf 65-Scandinavian Critical Care Trials Group Hydrocortisone for COVID-19 and Severe Hypoxia

Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (DEXA-COVID19)

Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and metaanalysis

Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. Diabetes & metabolic syndrome

Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert review of respiratory medicine

Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis

Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis. Polish archives of internal medicine

Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis

FIO2, fraction of inspired oxygen

NA, not applicable; RECOVERY, Randomized Evaluation of COVID-19 Therapy

Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia

Sepsis-3, Third International Consensus Definitions for Sepsis and Septic Shock

Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure. *data were extracted from Sterne et al Jama

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.